Triasima Portfolio Management inc. Grows Position in Gilead Sciences, Inc. $GILD

Triasima Portfolio Management inc. increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 12.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 39,111 shares of the biopharmaceutical company’s stock after acquiring an additional 4,445 shares during the quarter. Triasima Portfolio Management inc.’s holdings in Gilead Sciences were worth $4,341,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of GILD. Brighton Jones LLC boosted its stake in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 2,450 shares during the last quarter. Bison Wealth LLC purchased a new position in shares of Gilead Sciences during the 4th quarter worth $215,000. Sivia Capital Partners LLC boosted its position in shares of Gilead Sciences by 16.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after acquiring an additional 602 shares during the last quarter. Silver Oak Securities Incorporated purchased a new stake in shares of Gilead Sciences in the second quarter valued at about $415,000. Finally, Matrix Trust Co increased its position in Gilead Sciences by 9.0% during the second quarter. Matrix Trust Co now owns 1,295 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 107 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. Mizuho boosted their target price on shares of Gilead Sciences from $131.00 to $140.00 and gave the company an “outperform” rating in a report on Friday, November 21st. Morgan Stanley cut their target price on Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating for the company in a research note on Tuesday, January 13th. The Goldman Sachs Group upped their price target on Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a research note on Thursday, January 8th. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. Finally, Argus boosted their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $133.28.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the transaction, the chief financial officer directly owned 150,503 shares of the company’s stock, valued at $18,709,027.93. The trade was a 1.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Kelly A. Kramer sold 2,805 shares of the company’s stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $127.10, for a total value of $356,515.50. Following the sale, the director owned 1,339 shares in the company, valued at approximately $170,186.90. This trade represents a 67.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 136,757 shares of company stock worth $16,951,612 over the last 90 days. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Price Performance

GILD stock opened at $123.61 on Tuesday. The business’s fifty day moving average price is $123.49 and its 200 day moving average price is $118.20. Gilead Sciences, Inc. has a 12-month low of $91.84 and a 12-month high of $128.70. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The company has a market capitalization of $153.36 billion, a PE ratio of 19.21, a P/E/G ratio of 0.66 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.16 by $0.31. The company had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.Gilead Sciences’s revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the company posted $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Investors of record on Monday, December 15th were paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend was Monday, December 15th. Gilead Sciences’s dividend payout ratio is presently 48.99%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.